News | Aditum Bio

top of page

News: Latest News

News: Latest News

Latest News

PRESS RELEASE

NOV 7, 2024

Aditum Bio and Leads Biolabs Announce the Formation of Oblenio Bio to Develop a Tri-Specific T-Cell Engager for Autoimmune Disorders

IN THE NEWS

AUG 14, 2023

Lilly Completes Acquisition of Versanis Bio for $1.925 Billion

PRESS RELEASE

NOV 21, 2022

EmbarkNeuro Announces Initiation of Phase 2 Trial of ANC-501, a First-In-Class, V1b Receptor Antagonist for the Personalized Treatment of Depression

PRESS RELEASE

SEP 8, 2021

Via Nova Therapeutics Announces $20 Million Series A Financing from Aditum Bio to Advance Four Antiviral Programs

PRESS RELEASE

DEC 15, 2020

Aditum Bio Announces Formation of Third Company, Anteris Bio

IN THE NEWS

NOV 2, 2020

Novartis alums Jimenez, Fishman unveil their next act: Aditum Bio

IN THE NEWS

NOV 2, 2020

Japan’s Sosei allies with ex-Novartis team to develop neurological drug pipeline

PRESS RELEASE

SEP 21, 2023

Aditum Bio Announces Formation of Celexor Bio, Focused on Cell Depletion of Pathologic Cells in Autoimmune and Inflammatory Disorders

PRESS RELEASE

APR 27, 2023

Aditum Bio Announces Formation of Vitalli Bio, Focused on Immunological Disorders

PRESS RELEASE

NOV 15, 2021

Aditum Bio Announces Formation of Motric Bio, Focused on Spasticity Associated with Neurological Injuries and Disease

PRESS RELEASE

AUG 31, 2021

Versanis Bio Announces $70 million Series A Financing to Advance Bimagrumab for the Treatment of Obesity

IN THE NEWS

NOV 3, 2020

Novartis vets Jimenez, Fishman thread digital into fabric of new VC firm Aditum, launch Tempero

PRESS RELEASE

NOV 2, 2020

Aditum Bio, Co-Founded by Novartis Veterans Joe Jimenez and Dr. Mark Fishman, forms Second Company

PRESS RELEASE

SEP 21, 2023

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) application for VNT-101, a novel direct-acting antiviral against Influenza A virus

PRESS RELEASE

JAN 4, 2023

Tempero Bio Announces FDA Clearance of Investigational New Drug (IND) Application for TMP-301 for the Treatment of Alcohol and Other Substance Use Disorders

PRESS RELEASE

NOV 8, 2021

Aditum Bio announces the appointment of Stephen Kanes, M.D. Ph.D., as Chief Executive Officer of Ancora Bio

PRESS RELEASE

JUN 30, 2021

Aditum Bio Announces Formation of Ancora Bio, to Focus on Treatment Resistant Depression

IN THE NEWS

NOV 2, 2020

Joe Jimenez has one more thing to do in biopharma. And now he and Mark Fishman have a $133M stake to play the startup game

IN THE NEWS

NOV 2, 2020

‘Stealth’ VC firm Aditum Bio launches its second biotech startup

2020 News 1

2020 News 2

2020 News 3

bottom of page